ISSN: 2319-5894

Pharma Utility Volume 7, Issue 1, 2013

Review Article
Floating Drug Delivery Systems: A critical analysis
Author: Sudhir Pandya
NuLife Pharmaceuticals, Pimpri, Pune, MS, India. Pin- 411018
Email: pandyasudhir@hotmail.com
ABSTRACT
Oral controlled drug delivery systems should be designed in order to achieve more predictable
and increased bioavailability of drugs. Sophisticated oral dosage forms such as controlled drug
delivery systems are playing major role. Such systems release drug at predetermined rate, as
determined by drug pharmacokinetics and desired therapeutic concentration. While optimizing
the delivery systems physiological challenges, such as short gastric residency, varying gastric
emptying and other factors are always the point of focus. Approaches that are currently utilized
in the prolongation of the gastro residency include floating drug delivery systems (FDDS),
swelling and expanding systems, polymeric bioadhesive systems, high-density systems,
modified-shape systems and other delayed gastric emptying devices. It is evident from the recent
scientific and patent literature that an increased interest in novel dosage forms that are retained in
the stomach for a prolonged and predictable period of time exists today in academic and
industrial research groups. One of the most feasible approaches for achieving a prolonged and
predictable drug delivery profile in the GI tract is to control the gastric residence time (GRT).
Dosage forms with a prolonged GRT, i.e. gastro-retentive dosage forms (GRDFs), provide new
and important therapeutic options.
Keywords: floating drug delivery, oral drug delivery, and gastric emptying time, drug retention

http://www.pharmautility.com

ISSN: 2319-5894
Pharma Utility Volume 7, Issue 1, 2013

INTRODUCTION
The design of an oral controlled drug delivery system should be primarily aimed at achieving
more predictable and increased bioavailability of drugs. Over the years, oral dosage forms have
become increasingly sophisticated with major role being played by controlled release drug
delivery systems. Such systems release drug at predetermined rate, as determined by drug
pharmacokinetics and desired therapeutic concentration.
The development of such systems is precluded by several physiological difficulties such as:
a. Inability to restrain and localise the drug delivery system within the desired range of
gastrointestinal tract and
b. Highly variable nature of gastric emptying process.
This variability may lead to unpredictable bioavailability and times to achieve peak plasma
levels, since the majority of drugs are preferentially absorbed in upper part of small intestine [1].
Gastric emptying time in humans is normally 2-3 hours through the major absorption zone
(stomach or upper part of the intestine), which may lead to incomplete drug release from the
dosage form resulting in diminished efficacy of administered dose. The intimate contact of the
drug delivery system (DDS) with the absorbing membrane has the potential to maximize drug
absorption and may also influence the rate of drug absorption [2, 3].
It is evident from the recent scientific and patent literature that an increased interest in novel
dosage forms that are retained in the stomach for a prolonged and predictable period of time
exists today in academic and industrial research groups. One of the most feasible approaches for
achieving a prolonged and predictable drug delivery profile in the GI tract is to control the
gastric residence time (GRT). Dosage forms with a prolonged GRT, i.e. gastro-retentive dosage
forms (GRDFs), provide new and important therapeutic options.
http://www.pharmautility.com

ISSN: 2319-5894
Pharma Utility Volume 7, Issue 1, 2013

ADVANTAGES OF GRDFS
1. Sustained drug delivery:
Drug absorption from oral controlled release dosage forms is often limited by the short GRT
available for absorption. However, hydrodynamically balanced system (HBS) type forms
can remain in the stomach for several hours and, therefore, significantly prolong the GRT of
numerous drugs.
These special dosage forms are light, relatively large in size and do not easily pass through
the pylorus, which has an opening of approximately 0.9 1.9 cm [4]. It is worth noting here
that a prolonged GRT is not responsible for the slow absorption of a lipophilic drug such as
Isradipine that has been achieved with a floating modified-release capsule [5]. This is
because the major portion of drug release from modified-release capsule took place in the
colon, rather than in the stomach. However, the assumed prolongation in the GRT is
postulated to cause the sustained drug-release behaviour [6].
2. Site-specific drug delivery:
For drugs such as Furosemide and Riboflavin, which have limited absorption sites in the
small intestine rather than in the stomach, floating dosage form is a feasible approach. In
fact, the absorption of Furosemide has been found to be site-specific, the stomach being the
major site of absorption, followed by the duodenum [7].
This property prompted the development of a monolithic floating dosage form for
Furosemide, which could prolong the GRT, and thus its bioavailability was increased [8].
Recently, a bilayer floating capsule has been used to achieve local delivery of Misoprostol, a
synthetic prostaglandin E analog which is approved and marketed in the United States (as

http://www.pharmautility.com

ISSN: 2319-5894
Pharma Utility Volume 7, Issue 1, 2013

Cytotec by Pharmacia United States of America) for prevention of gastric ulcers caused by
non-steroidal anti-inflammatory drugs [9].
Floating tablets containing 2050 mg of 5-fluorouracil have been successfully evaluated in
four patients with stomach neoplasms in which tablets floated in the stomach for period of 2
hours after administration [10].
3. Pharmacokinetic advantages:
Drugs that have poor bioavailability owing to their absorption from the upper Gastro
Intestinal (GI) tract can be delivered efficiently, thereby maximizing their absorption and
improving their absolute bioavailability. For instance, a significant increase in the absolute
bioavailability of the floating dosage form of Furosemide has been obtained (42.9%),
compared to the commercial available tablet (Lasix; 33.4% Aventis Pharmaceuticals Inc.)
and enteric product (Lasix long; 29.5% Aventis Pharmaceuticals Inc). [11]
The reduced fluctuations in the plasma levels of drugs result from delayed gastric emptying.
After oral dosing the bioavailability of standard Madopar (Levodopa and Benserazide,
Roche USA) was found to be 6070%; the difference in bioavailability of standard and HBS
formulations seems to be due to incomplete absorption rather than an altered disposition of
the drug [12].
Cook et al. demonstrated that a HBS capsule containing iron salts has an increased efficacy
and reduced side effects. Floating dosage forms with sustained release characteristic can also
be expected to reduce the variability in transit performance [13] and various
pharmacokinetic parameters [14]. It might be expected that developing HBS dosage form for
Tacrine might provide a better delivery system and reduce its GI side effects in Alzheimers
http://www.pharmautility.com

ISSN: 2319-5894
Pharma Utility Volume 7, Issue 1, 2013

patients. In addition, buoyant delivery systems might provide a beneficial strategy for the
treatment of gastric and duodenal cancers [1]. The concept of Floating Drug Delivery
System (FDDS) has also been utilized in the development of various anti-reflux
formulations. (Figure 1)

Figure 1 HBS Capsule

Another therapeutic area in which FDDS can be explored is in the formulations intended for the
eradication of Helicobacter pylori, which is now believed to be the causative bacterium for
chronic gastritis and peptic ulcers. Although the bacterium is highly sensitive to most antibiotics,
its eradication from patients requires high concentrations of drug to be maintained within the
gastric mucosa for a long duration [15]. Recently Katayama et al [16] developed a sustained
release liquid preparation of Ampicillin using Sodium Alginate that spreads out and adheres to
the gastric mucosal surface whereby the drug is continuously released. Thus, it can be expected
that topical delivery of a narrow spectrum antibiotic through a FDDS may result in complete
http://www.pharmautility.com

ISSN: 2319-5894
Pharma Utility Volume 7, Issue 1, 2013

removal of the organisms in the fundal area of the gastric mucosa due to bactericidal drug levels
being reached in this area, and might lead to better treatment of peptic ulcer disease.
LIMITATIONS
One of the disadvantages of floating systems is that they require sufficiently high level of fluids
in the stomach for the drug delivery to float therein and to work efficiently. However, this
limitation can be overcome by coating the dosage form with bio adhesive polymers, thereby
enabling them to adhere to the mucous lining of the stomach wall. Alternatively, the dosage form
may be administered with a glass full of water (200250 ml). Floating systems are not feasible
for those drugs that have solubility or stability problems in gastric fluids. Drugs such as
Nifedipine, which is well absorbed along the entire GI tract and which undergoes significant
first-pass metabolism, may not be a desirable candidate for FDDS, since the slow gastric
emptying may lead to reduced systemic bioavailability [1]. Also there are limitations to the
applicability of FDDS for drugs that irritate gastric mucosa.
MECHANISTIC APPROACHES OF FDDS
Various attempts have been made to retain the dosage form in the stomach as a way of
increasing the retention time. These attempts include introducing floating dosage forms (gasgenerating systems and swelling or expanding systems), mucoadhesive systems, modified shape
systems, gastric-emptying delaying devices and co-administration of gastric-emptying delaying
drugs. Among these, the floating dosage forms have been used most commonly. However, most
of these approaches are influenced by a number of factors that affect their efficacy as a
gastroretentive system: [18, 19] (Figure 2)

http://www.pharmautility.com

ISSN: 2319-5894
Pharma Utility Volume 7, Issue 1, 2013

Figure 2 Mechanism of floating systems

(GF- Gastric Fluid, RW- Resultant Weight)
It is very important that the floatation occurs as rapidly as possible in order to avoid the
pharmaceutical composition being expelled from the stomach. It is considered that if it does not
float within three minutes following absorption in a fasting subject the probability that it is
evacuated from the stomach becomes unacceptable. [20]
FACTORS AFFECTING PERFORMANCE OF FDDS [21]
A. Dosage form related factors:
1. Density GRT is a function of dosage form buoyancy that is dependent on the density.
2. Size Dosage form units with a diameter of more than 7.5mm are reported to have
increased GRT compared with those with a diameter of 9.9mm.
3. Shape of dosage form Tetrahedron and ring shaped devices with a flexural

modulus

of 48 and 22.5 kilo pounds per square inch (KSI) are reported to have better GRT,
approximately 90% to 100% retention at 24 hours compared with other shapes;
4. Single or multiple unit formulation multiple unit formulations show a more predictable
release profile and insignificant impairing of performance due to
http://www.pharmautility.com

failure of units, allow

ISSN: 2319-5894
Pharma Utility Volume 7, Issue 1, 2013

co-administration of units with different release profiles or

substances and permit a larger margin of safety against

containing incompatible

dosage form failure compared

with single unit dosage forms.

B. Patient related factors:

Fed or unfed state Under fasting conditions, the GI motility is characterized by

periods of strong motor activity or the MMC that occurs every 1.5 to 2 hours. The
MMC sweeps undigested material from the stomach and, if the timing of
administration of the formulation coincides with that of the MMC, the GRT of the
unit can be expected to be very short. However, in the fed state, MMC is delayed and
GRT is considerably longer.

Nature of meal Feeding of indigestible polymers or fatty acid salts can change the
motility pattern of the stomach to a fed state, thus decreasing the gastric emptying
rate and prolonging drug release;

Caloric content GRT can be increased by four to ten hours with a meal that is high in
proteins and fats.

Frequency of feed The GRT can increase by over 400 minutes when successive
meals are given compared with a single meal due to the low

frequency of MMC.

Gender Mean ambulatory GRT in males (3.40.6hours) is less compared with their
age and race matched female counterparts (4.61.2 hours), regardless of the weight,
height and body surface.

Age Elderly people, especially those over 70, have a significantly longer GRT.

Posture GRT can vary between supine and upright ambulatory states of the patient.

Concomitant drug administration Anticholinergics like Atropine and Propantheline,

opiates like codeine and prokinetic agents like Metoclopramide and Cisapride affect
GRT.
http://www.pharmautility.com

ISSN: 2319-5894
Pharma Utility Volume 7, Issue 1, 2013

Biological factors Diabetes and Crohns disease alter GRT.

TECHNOLOGICAL DEVELOPMENTS
Floating systems, first described by Davis [22] in 1986 have bulk density lower than that of the
gastric fluid, and thus remains buoyant in stomach for a prolonged period. While the system is
floating on the gastric components, the drug is released slowly at the desired rate. This results in
increase in the GRT and a better control of fluctuations in the plasma drug concentrations.
Floating systems can be classified into two distinct categories, non-effervescent and effervescent
systems.
A. NON-EFFERVESCENT SYSTEMS
1. Colloidal gel barrier systems
Hydrodynamically balanced system (HBSTM) contain drug with gel forming hydrocolloids
meant to remain buoyant on the stomach contents. This prolongs GI residence time,
maximizes drug reaching its absorption site in the solution form, and hence is ready for
absorption. These systems incorporate high level (20 to 75 % w/w) of one or more gel
forming highly swellable cellulose type hydrocolloids [for eg. Hydroxyethyl cellulose
(HEC), Hydroxypropyl Cellulose (HPC) Hydroxypropyl Methyl Cellulose (HPMC), Sodium
Carboxy Methyl Cellulose (NaCMC) [23], polysaccharides and matrix forming polymers
such as polycarbophill, polyacrylates and polystyrene, incorporated either in tablets or
capsules. On coming in contact with the gastric fluid, the hydrocolloid in the system
hydrates and forms a colloidal gel barrier around its surface. (Figure 3)

http://www.pharmautility.com

ISSN: 2319-5894
Pharma Utility Volume 7, Issue 1, 2013

Figure 3 Intragastric floating tablet

This gel barrier controls the rate of the fluid penetration into the device and consequent
release of drug. [23] As the exterior surface of the dosage form goes in to the solution, the
gel layer is maintained by the adjacent hydrocolloid layer becoming hydrated. The air
trapped in by the swollen polymer maintains density less than unity and confers buoyancy to
these dosage forms.
The HBS TM must comply with three major criteria:
1. It must have sufficient structure to form cohesive gel barrier.
2. It must maintain an overall specific density lower than that of gastric contents.
3. It should dissolve slowly enough to serve as reservoir for the delivery system.
A bilayered tablet can also be prepared to contain one immediate release and other
sustained release layer (Figure 4)

http://www.pharmautility.com

ISSN: 2319-5894
Pharma Utility Volume 7, Issue 1, 2013

Figure 4

Bilayer intragastric floating tablet

Immediate release layer delivers the initial dose, whereas Sustained Release layer absorbs
gastric fluid and forms a colloidal gel barrier on its surface. This results in system with bulk
density lesser than that of gastric fluid and allows it to remain buoyant in the stomach for an
extended period of time [24].
A multi-layer, flexible, sheath-like device buoyant in gastric juice showing sustained release
characteristics has also been developed [25]. The device consisted of at least one selfsupporting carrier film made up of water insoluble polymer matrix having a drug
dispersed/dissolved therein, and a barrier film overlaying a carrier film. Both carrier and
barrier films were sealed together along their periphery and in such a way as to entrap a
plurality of small air pockets leading to buoyancy of laminated films.
2. Microporous compartment system.
This technology is based on encapsulation of a drug reservoir inside a microporous
compartment with aperture along its top and bottom walls. The peripheral walls of the drug
reservoir compartment are completely sealed to prevent any direct contact of gastric
mucosal surface with undissolved drug. In stomach, the floatation chamber containing
entrapped air causes the delivery system to float over the gastric contents. Gastric fluid
http://www.pharmautility.com

ISSN: 2319-5894
Pharma Utility Volume 7, Issue 1, 2013

enters through the aperture, dissolves the drug, and carries the dissolved drug for continuous
transport across the intestine for absorption. The microporous compartment system is shown
in (Figure 5) [26].

Figure 5

Microporous intragastric floating drug delivery device

Intragastric floating and sustained release granules of diclofenac sodium were developed
using HPC, Ethyl Cellulose and Calcium silicate as floating carriers, which had a
characteristically porous structure with numerous pores and a large individual pore volume
[26]. The coated granules acquire floating ability from the air trapped in the pores of
Calcium Silicate when they were coated with a polymer.
3. Alginate beads:
Multiunit floating dosage forms have been developed from freeze-dried Calcium alginate
[27]. Spherical beads of approximately 2.5mm in diameter can be prepared by dropping a
Sodium alginate solution in to aqueous solution of Calcium chloride, causing a precipitation
of Calcium alginate. The beads are then separated; snap frozen in liquid nitrogen, and
freeze-dried at - 40oC for 24 hours, leading to formation of porous system, which can
http://www.pharmautility.com

ISSN: 2319-5894
Pharma Utility Volume 7, Issue 1, 2013

maintain floating force for over 12 hrs. When compared with solid beads, which gave a short
residence time of 1 hour, these floating beads gave a prolonged residence time of more than
5.5 hours.
Floating systems comprising of Calcium alginate core separated by an air compartment from
a membrane of Calcium alginate or a Calcium alginate/Polyvinyl Alcohol (PVA) have also
been developed [28]. The porous structure generated by leaching of PVA (water soluble
additive in coating composition) was found to increase membrane permeability, preventing
the collapse of air compartment.
4. Hollow microspheres.
Hollow microspheres (micro balloons), loaded with Ibuprofen in their outer polymer shells
were prepared by novel emulsion solvent diffusion method. The ethanol: dichloromethane
solution of the drug and an enteric acrylic polymer was poured into an agitated aqueous
solution of PVA that was thermally controlled at 40oC. The gas phase generated in dispersed
polymer droplet by evaporation of dichloromethane formed an internal cavity in
microsphere of polymer with drug (Figure 6). The micro balloons floated continuously over
surface of acidic solution media containing surfactant for greater than 12 hours in vitro. The
drug release was high in pH 7.2 than in pH 6.8 [29].

http://www.pharmautility.com

ISSN: 2319-5894
Pharma Utility Volume 7, Issue 1, 2013

Figure 6 Mechanism of micro balloon formation by emulsion-solvent diffusion method.

5. Non Compressed Dosage form
This unique therapeutic dosage form comprises of therapeutically effective agent, gelling
agent in the concentration of 0.5 to 4 % along with 10 20% therapeutically acceptable inert
oil & water. The dosage form may also contain other conventional additives and excipients
such as thickening agents, surfactants, preservatives, bulking agents and antioxidants.[30]
These dosage forms, which are in the form of tablets, although not compressed, have
sufficient mechanical stability & hardness so that they will withstand the normal stress of
production, packaging and dispensing. They have a density which is less than one and
sufficiently low so that they will float on gastric fluid. Typically density is from about 0.6 to
0.95.
Except for agents which must be protected from in gastric fluid this novel dosage form is
applicable to therapeutic agents which include analgesics, anorexias, antacids, antibiotics,
antidiabetics,

antihistamines,

steroids,

antispasmodics,

cardiovascular

decongestants, muscle relaxants, diuretics, tranquilizers, & vitamins. [31]

http://www.pharmautility.com

preparations,

ISSN: 2319-5894
Pharma Utility Volume 7, Issue 1, 2013

B. Effervescent Systems:
A drug delivery system can be made to float in the stomach by incorporating a floating chamber,
which may be filled with vacuum, air or inert gas. The gas in floating chamber can be introduced
either by volatilization of an organic solvent or by effervescent reaction between organic acids
and bicarbonate salts.
1. Volatile liquid containing systems:
The GRT of a drug delivery system can be sustained by incorporating an inflatable chamber,
which contains a liquid, e.g. Ether, Cyclopentane, that gasifies at body temperature to cause
the inflation of the chamber in the stomach. These devices are osmotically controlled
floating systems containing a hollow deformable unit that can convert from a collapsed to an
expanded position, and returns to collapsed position after an extended period. A deformable
system consists of two chambers separated by an impermeable, pressure responsive,
movable bladder. The first chamber contains the drug and the second chamber contains
volatile liquid. The device inflates, and the drug is continuously released from the reservoir
into the gastric fluid. The device may also consist of bioerodible plug made up of PVA,
Polyethylene, etc. that gradually dissolves causing the inflatable chamber to release gas and
collapse after a predetermined time to permit the spontaneous ejection of the inflatable
system from the stomach (Figure 7) [32].

http://www.pharmautility.com

ISSN: 2319-5894
Pharma Utility Volume 7, Issue 1, 2013

Figure 7

Intragastric osmotic controlled drug delivery system

Intragastric osmotically controlled drug delivery system consists of an osmotic pressure

controlled drug delivery device and an inflatable floating support in bioerodible capsule.
When the device reaches the stomach, bioerodible capsule quickly disintegrates to release
the drug delivery system. The floating support is made up of a deformable hollow polymeric
bag containing a liquid that gasifies at body temperature to inflate the bag. The osmotic
pressure controlled part consists of two compartments, a drug reservoir compartment, and an
osmotically active agent containing compartment. The drug reservoir compartment is
enclosed in a pressure responsive collapsible bag, which is impermeable to vapours and
liquid, and has a drug delivery orifice. The osmotic compartment contains an osmotically
active salt, and is enclosed within semipermeable housing. In stomach, water is absorbed
through the semipermeable membrane into the osmotic compartment to dissolve the salt. An
osmotic pressure is thus created, which acts on collapsible bag, and in turn forces the drug
reservoir compartment to reduce its volume and release the drug solution through the
http://www.pharmautility.com

ISSN: 2319-5894
Pharma Utility Volume 7, Issue 1, 2013

delivery orifice. The floating support also contains a bioerodible plug that erodes after a
predetermined time to deflate the support, which is then excreted from the stomach (Figure
8) [33].

2. Gas generating system:

These buoyant delivery systems utilize effervescent reaction between carbonate/ bicarbonate
salts and citric/ tartaric acid to liberate CO2, which gets entrapped in the gellified
hydrocolloid layer of the system, thus decreasing its specific gravity and making it float over
chyme. These tablets may be either single layered wherein the CO2 generating components
are intimately mixed within the tablet matrix, or they may be bilayered in which the gas
generating components are compressed in one hydrocolloid containing layer, and the drug in
outer layer for sustained release effect.
http://www.pharmautility.com

ISSN: 2319-5894
Pharma Utility Volume 7, Issue 1, 2013

Multi-unit types of floating pills (Figure 9), which generate CO2, have also been developed
[34]. The system consists of sustained release pill as a seed, surrounded by double layers.
The inner layer is an effervescent layer containing sodium bicarbonate and tartaric acid. The
outer layer is swellable membrane layer. These kinds of systems float completely within 10
minutes, and remain floating over extended period of 5-6 hours [35].

http://www.pharmautility.com

ISSN: 2319-5894
Pharma Utility Volume 7, Issue 1, 2013

Figure 9 Multiple unit oral floating dosage systems

http://www.pharmautility.com

ISSN: 2319-5894
Pharma Utility Volume 7, Issue 1, 2013

EVALUATION OF FDDS
Evaluation of a drug product is a tool to ensure
(1) performance characteristics, and
(2) control batch-to-batch quality,
(3) General appearance, hardness and friability, drug content, weight variation, uniformity of
content, drug release, etc, for gastro retentive performance.
1. Floating time:
The test for buoyancy is usually performed in simulated gastro intestinal fluids maintained at
37 0C. The floating time is determined by using the USP dissolution apparatus containing
900ml of 0.1N HCL as the testing medium maintained at 37 0C. The time for which the
dosage form floats is termed as the floating or floatation time.[36]
2. Specific gravity:
The specific gravity of floating systems can be determined by the displacement method
using benzene as a displacing medium [37].
3. Resultant weight:
Bulk density and floating duration have been the main parameters to describe the adequacy
of dosage forms buoyancy. Resultant weight, corresponds to the vector sum of buoyancy
(Fbuoy) and gravity (Fgrav) forces acting on the object. [38]
F= Fbuoy - Fgrav
F= dfgV-dsgV= (df-ds) gV
F = (df-M/V) gV
Where, F is total vertical force (resultant weight of the object), g is the acceleration due to
gravity, df is the fluid density, ds is the object density, M is the object mass and V is the
volume of the object. By convention, a positive resultant weight signifies force F exerted
http://www.pharmautility.com

ISSN: 2319-5894
Pharma Utility Volume 7, Issue 1, 2013

vertically upwards and that the object is able to float, whereas a negative resultant weight
means that the force F acts vertically downwards and the object sinks (Figure 10). The
crossing of the zero base line by the resultant weight curve from positive towards negative
values indicate transition of the dosage form from floating to non-floating conditions.
Intersection of lines consequently corresponds, on time axis, to the floating time of the
dosage form.

http://www.pharmautility.com

ISSN: 2319-5894
Pharma Utility Volume 7, Issue 1, 2013

Figure 10 Forces acting during buoyancy and the floating time

http://www.pharmautility.com

ISSN: 2319-5894
Pharma Utility Volume 7, Issue 1, 2013

4. Gamma scintigraphic studies:

Gamma scintigraphy has been established as the method of choice for in vivo imaging studies of
formulations. In gamma scintigraphy, the formulation is visualised by gamma radiation emitted
from trace amounts of one or two radionuclides that have to be included in the dosage form. The
location of a single unit in the GI tract is determined from the position of the gamma camera
image. Since no image of the GI anatomy is obtainable, an external radioactive marker may be
positioned at a well defined anatomical position as a reference point in the determination of the
radio labelled formulation. [39]
CONCLUSION
The currently available polymer-mediated non-effervescent and effervescent FDDS, designed on
the basis of delayed gastric emptying and buoyancy principles, appear to be an effective and
rational approach to the modulation of controlled oral drug delivery. This is evident from the
number of commercial products and the myriad of patents issued in this field. The FDDS become
an additional advantage for drugs that are absorbed primarily in the upper segments of GI tract,
i.e., the stomach, duodenum and jejunum. Some of the unresolved, critical issues related to the
rational development of
FDDS include
1. The quantitative efficiency of FDDS in fasted and fed states.
2. Role of the buoyancy in enhancing GRT of the FDDS and
3. Correlation between prolonged GRT and Sustained Release /Pharmacokinetic
characteristics.
Finally, with an increasing understanding of polymer behaviour and the role of the biological
factors mentioned above, it is suggested that future research work in the FDDS should be aimed
at discovery means to accurately control the drug input rate into the GI tract for the optimisation
of pharmacokinetic and toxicological profiles of medicinal agents. The next two decades might
http://www.pharmautility.com

ISSN: 2319-5894
Pharma Utility Volume 7, Issue 1, 2013

result in the availability of new products with new therapeutic possibilities and substantial
benefits for patients. Soon, novel gastroretentive products with release and absorption phases of
approximately 24 hrs may replace the so-called once-a-day formulations.
Drugs

Dosage forms

GRT (h)
NFDS*

FDDS

References

Diazepam

Capsules

1-1.5

4-10

[23,38,40]

(Moricizine HCl)

Tablets

1-1.5

>6

[41]

Gentamycin sulfate

Tablets

1-2

>4

[42]

Isradipine

Capsules

0.51-2.87

2.4-4.8

[5]

Metoprolol tartrate

Tablets

1-1.5

5-6

[43]

Miocamycin

Tablets

3-4

>7

[44]

Pepstatin

Minicapsules

NR

3-5

[45]

Salbutamol sulfate

Capsules

NR

8-9

[46]

Tranilast

Microcapsules

NR

>3

[4]

*Non floating drug system

Table: 1 Comparison of GRTs of floating and nonfloating solid dosage form

http://www.pharmautility.com

ISSN: 2319-5894
Pharma Utility Volume 7, Issue 1, 2013

REFERENCES
[1]

N. Rouge, P. Buri, E. Doelker, Drug absorption sites in the gastrointestinal tract and
dosage forms for site-specific delivery, Int. J. Pharm. 136 (1996) 117139.

[2]

S. Desai, A novel floating controlled release drug delivery system based on a dried gel
matrix, M.S. thesis, St. Johns University, Jamaica, NY, 1984.

[3]

J.T. Fell, Targeting of drugs and delivery systems to specific sites in the gastrointestinal
tract, J. Anat. 189 (1996) 517 519.

[4]

J.A. Fix, R. Cargill, K. Engle, Controlled gastric emptying.III. Gastric residence time of a
nondisintegrating geometric shape in human volunteers, Pharm. Res. 10 (1993) 1087
1089.

[5]

N. Mazer, E. Abisch, J.C. Gfeller, R. Laplanche, P. Bauer- feind, M. Cucala, M.

Lukachich, A. Blum, Intragastric behavior and absorption kinetics of a normal and
floating modified-release capsule of iSustained Releaseadipine under fasted and fed
conditions, J. Pharm. Sci. 8 (1988) 647657.

[6]

A. Rubinstein, D.R. Friend, Specific delivery to the gastroin-testinal tract, in: A.J. Domb
(Ed.), Polymeric Site-Specific Pharmacotherapy, Wiley, Chichester, 1994, pp. 282283.

[7]

W.A. Ritschel, A. Menon, A. Sakr, Biopharmaceutic evaluation of furosemide as a

potential candidate for a modified release peroral dosage form, Methods Find. Exp. Clin.
Pharmacol. 13 (1991) 629636.

[8]

A. Menon, W.A. Ritschel, A. Sakr, Development and evaluation of a monolithic floating

dosage form for furosemide, J. Pharm. Sci. 83 (1994) 239245.

[9]

M. Oth, M. Franz, J. Timmermans, A. Moes, The bilayer floating capsule: a stomachdirected drug delivery system for misoprostol, Pharm. Res. 9 (1992) 298302.

[10]

K. Watanabe, Y. Machida, K. Takayama, M. Iwata, T. Nagai et al.Preparation and

evaluation of intragastric floating tablet having pH independent buoyancy and sustained
release property, Arch. Pract. Pharm. Yakuzaigaku 53 (1993) 17.
http://www.pharmautility.com

ISSN: 2319-5894
Pharma Utility Volume 7, Issue 1, 2013

[11]

www.aventis-us.com.

[12]

S. L. Malcolm, J. G. Allen, H. Bird, N. P. Quinn, M. H. Marion, C. D. Marsden, C. G. O

Leary, Single-dose pharmacokinetics of Madopar HBS in patients and effect of food and
antacid on the absorption of Madopar HBS in volunteers, Eur. Neurol. 27 (1987) 28S
35S.

[13]

J. Timmermans, A.J. Moes, Factors controlling the buoyancy and gastric retention
capabilities of floating matrix capsules: new data for reconsidering the controversy, J.
Pharm. Sci. 83(1994) 1824.

[14]

C. Crevoisier, B. Hoevels, G. Zurcher, M. Da Prada, Bioavailability of L-dopa after

Madopar HBS administration in healthy volunteers, Eur. Neurol. 27 (1987) 36S46S.

[15]

M.J. Blaser, Hypotheses on the pathogenesis and natural history of Helicobacter pyloriinduced inflammation, Gastroenterology 102 (1992) 720727.

[16]

H. Katayama, T. Nishimura, S. Ochi, Y. Tsuruta, Y.Yamazaki, Sustained release liquid

preparation using sodium alginate for eradication of Helicobacter pylori, Biol.Pharm.
Bull. 22 (1999) 5560.

[17]

S. Desai, S. Bolton, A floating controlled-release drug delivery systems: in vitroin vivo

evaluation, Pharm. Res. 10 (1993) 13211325.

[18]

P. Mojaverian, P.H. Vlasses, P.E. Kellner, M.L. Rocci Jr., Effects of gender, posture, and
age on gastric residence time of an indigestible solid: pharmaceutical considerations,
Pharm. Res. 10 (1988) 639644.

[19]

J. Timmermans, A.J. Moes, How well do floating dosage forms float?, Int. J. Pharm. 62
(1990) 207216.

[20]

Jerome Besse, Listrac Medoc, Gastric retained pharmaceutical composition and methods
for its use, US Patent Pub. No. US 2001/0046473 A1,Nov. 29, 2001.

[21]

S. Garg, S. Sharma, Gastroretentive drug delivery systems, Business Briefings,

Pharmatech 2003, 162-166.
http://www.pharmautility.com

ISSN: 2319-5894
Pharma Utility Volume 7, Issue 1, 2013

[22]

S.S. Davis, A.F. Stockwell, M.J. Taylor, J.G. Hardy, D.R. Whalley, C.G. Wilson, H.
Bechgaard, F.N. Christensen, The effect of density on the gastric emptying of single- and
multiple-unit dosage forms, Pharm. Res. 3 (1986) 208213.

[23]

P.R. Sheth, J. Tossounian, The hydrodynamically balanced system (HBSE): a novel drug
delivery system for oral use, Drug Dev. Ind. Pharm. 10 (1984) 313339.

[24]

A.K. Hilton, P.B. Deasy, In vitro and in vivo evaluation of an oral sustained-release
floating dosage form of amoxycillin trihydrate, Int. J. Pharm. 86 (1992) 7988.

[25]

S.B. Mitra, Sustained release oral medicinal delivery device, US Patent 4, 451, 260, May
29, 1984.

[26]

Roy. Harrigan. M, Drug Delivery device for preventing contact of undissolved drug with
stomach lining. U.S.Patent No. 4055178. March 10, 1976.

[27]

H. Yuasa, Y. Takashima, Y. Kanaya, Studies on the development of intragastric floating

and sustained release preparation. I. Application of calcium silicate as a floating
carrier,Pharm. Bull. 44 (1996) 13611366.

[28]

L. Whitehead, J.T. Fell, J.H. Collett, H.L. Sharma, A.-M. Smith, Floating dosage forms:
an in vivo study demonstrating prolonged gastric retention, J. Control. Release 55 (1998)
312.

[29]

V. Iannuccelli, G. Coppi, R. Sansone, G. Ferolla, Air compartment multiple-unit system

for prolonged gastric residence. Part II. In vivo evaluation, Int. J. Pharm. 174 (1998) 55
62. (1997) 165171.

[30]

Bolton Sanford, Izevbehai, Philip H. Desai Subhash, Floating sustained release

therapeutic compositions, US Patent 4,814,178, March 21, 1989.

[31]

Sanford Bolton and Subhash Desai, Floating sustained release therapeutic compositions,
US Patent 4,814,179, March 21, 1989.

[32]

Y. Kawashima, T. Niwa, H. Takeuchi, T. Hino, Y. Ito, Preparation of multiple unit

hollow microspheres (microballoons) with acrylic resin containing tranilast and their drug
http://www.pharmautility.com

ISSN: 2319-5894
Pharma Utility Volume 7, Issue 1, 2013

release characteristics (in vitro) and floating behavior (in vivo) J. Control. Release 16
(1991) 279290.
[33]

A.S. Michaels, J.D. Bashwa, A. Zaffaroni, Integrated device for administering beneficial
drug at programmed rate, US Patent 3, 901, 232, August 26, 1975.

[34]

A.S. Michaels, Drug delivery device with self actuated mechanism for retaining device in
selected area, US Patent 3, 786, 813, January 22, 1974.

[35]

M. Ichikawa, S. Watanabe, Y. Miyake, A new multiple-unit oral floating dosage systems.

I: Preparation and in vitro evaluation of floating and sustained-release characteristics, J.
Pharm. Sci. 80 (1991) 10621066.

[36]

V. Pillay, R. Fassihi, Evaluation and comparison of dissolution data derived from

different modified release dosage forms: an alternative method, J. Control. Release 55
(1998) 4555.

[37]

S. Sangekar, W.A. Vadino, I. Chaudry, A. Parr, R. Beihn, G.Digenis, Evaluation of the

effect of food and specific gravity of tablets on gastric retention time, Int. J. Pharm. 35
(1987) 187191.

[38]

S.A. Muller-Lissner, N. Will, W. Muller-Duysing, F. Heinzel, A.L. Blum, A floating

capsule with slow release of drugs: a new method of oral drug medication, Dutch. Med.
Woch-enschr. 106 (1981) 11431147, Article in German

[39]

J. Timmermans, B. Van Gansbeke, A.J. Moes, Assessing by gamma scintigraphy the in

vivo buoyancy of dosage forms release, having known size and floating force profiles as
a function of time, Proc. 5th Int. Conf. Pharm. Technol., vol. I, APGI, Pharmazie 50
(1995) 769770.

[40]

J.H. Gustafson, L. Weissman, R.E. Weinfeld, A.A. Holazo,K.-C. Khoo, S.A. Kaplan,
Clinical bioavailability evaluation of a controlled release formulation of diazepam, J.
Pharmacokinet. Biopharm. 9 (1981) 679691.

http://www.pharmautility.com

ISSN: 2319-5894
Pharma Utility Volume 7, Issue 1, 2013

[41]

B.M. Regmi, J.P. Liu, X.D. Tu, Studies on ethmozine (EMZ)Sustained release tablets,
remaining-floating in stomach, Yao Hsueh Hsueh Pao 31 (1996) 5458, Abstract in
English, Article in Chinese.

[42]

W.L. Xu, X.D. Tu, Z.D. Lu, Development of gentamicin sulfate sustained-release tablets
remaining-floating in stomach, Yao Hsueh Hsueh Pao 26 (1991) 541545, Abstract in
English, Article in Chinese.

[43]

S.L. Li, X.D. Tu, F.F. Mao, Development and pharmacokinetic study of metoprolol
tartrate controlled-release remaining-floating in stomach, Yao Hsueh Hsueh Pao 24
(1989) 381386, Abstract in English, Article in Chinese.

[44]

Y. Diao, X.D. Tu, Development and pharmacokinetic study of miocamycin sustainedrelease tablets remaining-floating in stomach, Yao Hsueh Hsueh Pao 26 (1991) 695700,
Abstract in English, Article in Chinese

[45]

H. Umezawa, Pepstatin floating minicapsules, US Patent 4, 101, 650, July 18, 1978.

[46]

V.B.M. Babu, R.K. Khar, In vitro and in vivo studies of sustained-release floating dosage
forms containing salbutamol sulfate, Pharmazie 45 (1990) 268270.

[47]

N. K. Jain, Progress in controlled and Novel drug delivery, First edition ,CBS publishers,
New Delhi, (2001), 76-95.

[48]

B.M. Singh and K. H. Kim, Floating drug delivery system; An approach to controlled
drug delivery via gastric retention, J. Control. Release, 63 (2000), 235-259.

How to cite this article

Pandya S. Floating drug delivery systems: A critical analysis. Pharma Utility. 2013; 7(1)

http://www.pharmautility.com